EP About this file: EP2305282

EP2305282 - Prevention and treatment of amyloidogenic disease [Right-click to bookmark this link]
Status	Patent revoked Status updated on 18.11.2016 Database last updated on 05.04.2025
Most recent event Tooltip	13.01.2017	Lapse of the patent in a contracting state New state(s): CH, LI	published on 15.02.2017 [2017/07]
Applicant(s)	For all designated states Janssen Alzheimer Immunotherapy Airton Road Tallaght Dublin 24 / IE
	[2013/28]
Former [2011/14]	For all designated states Janssen Alzheimer Immunotherapy Little Island Industrial Estate Little Island, County Cork / IE
Inventor(s)	01 / Schenk, Dale B. 1542 Los Altos Drive Burlingame, CA 94010 / US
	[2013/28]
Former [2011/14]	01 / Schenk, Dale B. 1542 Los Altos Drive Burlingame, CA 94010 / US
Representative(s)	Bullett, Rachel Margaret, et al Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB
	[N/P]
Former [2011/14]	Bullett, Rachel Margaret, et al Carpmaels & Ransford One Southampton Row London WC1B 5HA / GB
Application number, filing date	10182575.0	30.11.1998
	[2011/14]
Priority number, date	US19970067740P	02.12.1997 Original published format: US 67740 P
	US19980080970P	07.04.1998 Original published format: US 80970 P
	[2011/14]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	EP2305282
	Date:	06.04.2011
	Language:	EN
	[2011/14]
	Type:	A3 Search report
	No.:	EP2305282
	Date:	18.05.2011
	[2011/20]
	Type:	B1 Patent specification
	No.:	EP2305282
	Date:	10.07.2013
	Language:	EN
	[2013/28]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	14.04.2011
Classification	IPC:	A61K38/00, A61K38/28, A61K9/26, A61K33/06	[2011/14]
	CPC:	C07K16/18 (EP,US); A61K31/00 (EP,US); A61K31/739 (EP,US); A61K38/1709 (EP,US); A61K38/193 (EP,US); A61K39/0007 (EP,US); (+) A61K47/646 (EP,US); A61K9/2031 (EP,US); A61K9/2054 (EP,US); A61K9/4866 (EP,US); A61P25/00 (EP); A61P25/28 (EP); A61P37/00 (EP); A61P43/00 (EP); C07K14/4711 (EP,US); A61K2039/505 (EP,US); A61K2039/53 (EP,US); A61K2039/55505 (EP,US); A61K2039/55555 (EP,US); A61K2039/55566 (EP,US); A61K2039/55572 (EP,US); A61K2039/55577 (EP,US); A61K2039/6037 (EP,US); A61K2039/605 (EP,US); A61K39/00 (EP,KR,US); A61K9/0019 (EP,US); A61K9/2009 (EP,US); A61K9/7023 (EP,US); C07K2317/24 (EP,US); C07K2317/567 (EP,US); C07K2319/00 (EP,US) (-)
	C-Set:	A61K38/193, A61K2300/00 (EP,US)
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [2011/14]
Extension states	AL	17.11.2011
	LT	17.11.2011
	LV	17.11.2011
	MK	01.12.2011
	RO	17.11.2011
	SI	17.11.2011
Title	German:	Vorbeugung und Behandlung von amyloidogener Krankheit	[2011/14]
	English:	Prevention and treatment of amyloidogenic disease	[2011/14]
	French:	Prévention et traitement de maladie amyloidogène	[2011/14]
Examination procedure	17.11.2011	Examination requested [2011/52]
	28.12.2011	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
	07.03.2012	Amendment by applicant (claims and/or description)
	21.05.2012	Despatch of a communication from the examining division (Time limit: M02)
	29.05.2012	Observations by third parties
	31.07.2012	Reply to a communication from the examining division
	17.01.2013	Communication of intention to grant the patent
	22.05.2013	Fee for grant paid
	22.05.2013	Fee for publishing/printing paid
Parent application(s) Tooltip	EP08011409.3 / EP1994937
	EP98961833.5 / EP1033996
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP19980961833) is 02.08.2005
Opposition(s)	Opponent(s)	01 09.04.2014 13.05.2014 ADMISSIBLE Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen Howard Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB
		02 09.04.2014 13.05.2014 ADMISSIBLE F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
		03 10.04.2014 13.05.2014 ADMISSIBLE Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Tuxworth, Pamela M. J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
		04 09.04.2014 13.05.2014 ADMISSIBLE H. Lundbeck A/S Ottilavej 9 2500Valby / DK Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		05 10.04.2014 28.09.2015 WITHDRAWN Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Spinner, David Richard Novartis Pharma AG Patent Department 4002 Basel / CH
		06 10.04.2014 14.05.2014 ADMISSIBLE Biogen Inc. 225 Binney Street Cambridge MA 02142 / US Opponent's representative Weiss, Wolfgang Weickmann & Weickmann Patent- und Rechtsanwälte PartmbB Postfach 860 820 81635 München / DE
		[N/P]
	Former [2016/24]
	Opponent(s)	01 09.04.2014 13.05.2014 ADMISSIBLE Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen H. Eli Lilly and Company Ltd European Patent Operations Lilly Research Centre Erl Wood Manor, Sunninghill Road Windlesham, Surrey, GU20 6PH / GB
		02 09.04.2014 13.05.2014 ADMISSIBLE F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
		03 10.04.2014 13.05.2014 ADMISSIBLE Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Tuxworth, Pamela M. J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
		04 09.04.2014 13.05.2014 ADMISSIBLE H. Lundbeck A/S Ottilavej 9 2500Valby / DK Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		05 10.04.2014 28.09.2015 WITHDRAWN Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Spinner, David Richard Novartis Pharma AG Patent Department 4002 Basel / CH
		06 10.04.2014 14.05.2014 ADMISSIBLE Biogen Inc. 225 Binney Street Cambridge MA 02142 / US Opponent's representative Weiss, Wolfgang Weickmann & Weickmann Patentanwälte PartmbB Postfach 860 820 81635 München / DE
	Former [2015/45]
	Opponent(s)	01 09.04.2014 13.05.2014 ADMISSIBLE Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen H. Eli Lilly and Company Ltd European Patent Operations Lilly Research Centre Erl Wood Manor, Sunninghill Road Windlesham, Surrey, GU20 6PH / GB
		02 09.04.2014 13.05.2014 ADMISSIBLE F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
		03 10.04.2014 13.05.2014 ADMISSIBLE Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Tuxworth, Pamela M. J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
		04 09.04.2014 13.05.2014 ADMISSIBLE H. Lundbeck A/S Ottilavej 9 2500Valby / DK Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		05 10.04.2014 28.09.2015 WITHDRAWN Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Spinner, David Richard Novartis Pharma AG Patent Department 4002 Basel / CH
		06 10.04.2014 14.05.2014 ADMISSIBLE Biogen Inc. 250 Binney Street Cambridge, MA 02142 / US Opponent's representative Weiss, Wolfgang Weickmann & Weickmann Patentanwälte Postfach 86 08 20 81635 München / DE
	Former [2015/43]
	Opponent(s)	01 09.04.2014 13.05.2014 ADMISSIBLE Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen H. Eli Lilly and Company Ltd European Patent Operations Lilly Research Centre Erl Wood Manor, Sunninghill Road Windlesham, Surrey, GU20 6PH / GB
		02 09.04.2014 13.05.2014 ADMISSIBLE F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
		03 10.04.2014 13.05.2014 ADMISSIBLE Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Tuxworth, Pamela M. J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
		04 09.04.2014 13.05.2014 ADMISSIBLE H. Lundbeck A/S Ottilavej 9 2500Valby / DK Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		05 10.04.2014 14.05.2014 ADMISSIBLE Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Spinner, David Richard Novartis Pharma AG Patent Department 4002 Basel / CH
		06 10.04.2014 14.05.2014 ADMISSIBLE Biogen Inc. 250 Binney Street Cambridge, MA 02142 / US Opponent's representative Weiss, Wolfgang Weickmann & Weickmann Patentanwälte Postfach 86 08 20 81635 München / DE
	Former [2015/38]
	Opponent(s)	01 09.04.2014 13.05.2014 ADMISSIBLE Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen H. Eli Lilly and Company Ltd European Patent Operations Lilly Research Centre Erl Wood Manor, Sunninghill Road Windlesham, Surrey, GU20 6PH / GB
		02 09.04.2014 13.05.2014 ADMISSIBLE F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
		03 10.04.2014 13.05.2014 ADMISSIBLE Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Tuxworth, Pamela M. J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
		04 09.04.2014 13.05.2014 ADMISSIBLE H. Lundbeck A/S Ottilavej 9 2500Valby / DK Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		05 10.04.2014 14.05.2014 ADMISSIBLE Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Spinner, David Richard Novartis Pharma AG Patent Department 4002 Basel / CH
		06 10.04.2014 14.05.2014 ADMISSIBLE Biogen Idec Inc. 133 Boston Post Road Weston, MA 02493 / US Opponent's representative Weiss, Wolfgang Weickmann & Weickmann Patentanwälte Postfach 86 08 20 81635 München / DE
	Former [2015/35]
	Opponent(s)	01 09.04.2014 13.05.2014 ADMISSIBLE Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen H. Eli Lilly and Company Ltd European Patent Operations Lilly Research Centre Erl Wood Manor, Sunninghill Road Windlesham, Surrey, GU20 6PH / GB
		02 09.04.2014 13.05.2014 ADMISSIBLE F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
		03 10.04.2014 13.05.2014 ADMISSIBLE Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Woods, Geoffrey Corlett J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
		04 09.04.2014 13.05.2014 ADMISSIBLE H. Lundbeck A/S Ottilavej 9 2500Valby / DK Opponent's representative Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
		05 10.04.2014 14.05.2014 ADMISSIBLE Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Spinner, David Richard Novartis Pharma AG Patent Department 4002 Basel / CH
		06 10.04.2014 14.05.2014 ADMISSIBLE Biogen Idec Inc. 133 Boston Post Road Weston, MA 02493 / US Opponent's representative Weiss, Wolfgang Weickmann & Weickmann Patentanwälte Postfach 86 08 20 81635 München / DE
	Former [2014/21]
	Opponent(s)	01 09.04.2014 ADMISSIBLE Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen H. Eli Lilly and Company Ltd European Patent Operations Lilly Research Centre Erl Wood Manor, Sunninghill Road Windlesham, Surrey, GU20 6PH / GB
		02 09.04.2014 ADMISSIBLE F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Siebertstrasse 4 81675 München / DE
		03 10.04.2014 Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Woods, Geoffrey Corlett J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
		04 09.04.2014 ADMISSIBLE H. Lundbeck A/S Ottilavej 9 2500Valby / DK Opponent's representative HOFFMANN EITLE Patent- und Rechtsanwälte Arabellastrasse 4 81925 München / DE
		05 10.04.2014 WITHDRAWN Novartis AG Lichtstrasse 35 4065 Basel / CH Opponent's representative Spinner, David Richard Novartis Pharma AG Patent Department 4002 Basel / CH
		06 10.04.2014 Biogen Idec MA Inc. 133 Boston Post Road Weston, MA 02493 / US Opponent's representative Weiss, Wolfgang Weickmann & Weickmann Patentanwälte Postfach 86 08 20 81635 München / DE
	Former [2014/20]
	Opponent(s)	01 09.04.2014 Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US Opponent's representative Ingham, Stephen H. Eli Lilly and Company Ltd European Patent Operations Lilly Research Centre Erl Wood Manor, Sunninghill Road Windlesham, Surrey, GU20 6PH / GB
		02 09.04.2014 F.Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH Opponent's representative Vossius & Partner Siebertstrasse 4 81675 München / DE
		03 10.04.2014 Leeming, John Gerard J.A. Kemp & Co. 14 South Square Gray's Inn London WC1R 5JJ / GB Opponent's representative Woods, Geoffrey Corlett J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB
	23.05.2014	Invitation to proprietor to file observations on the notice of opposition
	03.02.2015	Reply of patent proprietor to notice(s) of opposition
	01.10.2015	Cancellation of oral proceeding that was planned for 28.04.2016
	28.04.2016	Date of oral proceedings
	08.06.2016	Cancellation of oral proceeding that was planned for 22.06.2016
	22.06.2016	Date of oral proceedings
	04.07.2016	Despatch of communication that the patent will be revoked
	09.11.2016	Legal effect of revocation of patent [2016/51]
Appeal following opposition	14.09.2016	Appeal received No. T2144/16
	09.11.2016	Result of appeal procedure: appeal of the proprietor withdrawn
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
	07.03.2012	Request for further processing filed
	07.03.2012	Full payment received (date of receipt of payment) Request granted
	22.03.2012	Decision despatched
Fees paid	Renewal fee
	27.01.2011	Renewal fee patent year 03
	27.01.2011	Renewal fee patent year 04
	27.01.2011	Renewal fee patent year 05
	27.01.2011	Renewal fee patent year 06
	27.01.2011	Renewal fee patent year 07
	27.01.2011	Renewal fee patent year 08
	27.01.2011	Renewal fee patent year 09
	27.01.2011	Renewal fee patent year 10
	27.01.2011	Renewal fee patent year 11
	27.01.2011	Renewal fee patent year 12
	27.01.2011	Renewal fee patent year 13
	14.11.2011	Renewal fee patent year 14
	13.11.2012	Renewal fee patent year 15
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	CH	10.07.2013
	CY	10.07.2013
	LI	10.07.2013
	MC	10.07.2013
	[2017/07]
Former [2014/33]	CY	10.07.2013
	MC	10.07.2013
Former [2014/10]	CY	10.07.2013
Documents cited:	Search	[XY]WO9116819 (MOLECULAR RX INC [US]);
		[Y]WO9400153 (SMITHKLINE BEECHAM BIOLOG [BE], et al);
		[X]EP0683234 (TAKEDA CHEMICAL INDUSTRIES LTD [JP]);
	by applicant	US4666829
		GB2220211
		WO9007861
		WO9014837
		WO9110741
		US5057540
		WO9117271
		WO9118980
		WO9201047
		WO9213069
		EP0526511
		WO9306121
		US5208036
		WO9312227
		US5264618
		US5279833
		US5283185
		WO9408051
		US5314813
		WO9412629
		WO9505853
		US5399346
		WO9512608
		WO9530642
		WO9535503
		US5612486
		WO9717613
		WO9717614
	other	EP1033996
		EP1690547

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.32; 35p